It is well documented that people with SMI die 10 to 15 years earlier than the general population, largely due to cardiovascular disease
, including heart disease, heart attack and stroke.
However, the exact mechanisms by which maternal obesity increases the risk of metabolic and cardiovascular disease
in the offspring have not been established.
And to help people who already have cardiovascular disease
, it should train a Heart Corps of thousands of non-physician specialists who would help motivate patients to adopt healthy lifestyles.
Possible benefits include reduced risk of cardiovascular disease
, cancer, age-related macular degeneration and cataracts.
Researchers found in the early 1960s that the difference between the blood pressure taken from a person's arm and lower leg could predict future cardiovascular disease
Patients benefit from the dual effect of folic acid, combined with primorine, a novel carbonyl-trapping combination, thus reducing the risk of developing cardiovascular disease
These results confirm our in vitro observations and suggest that increased vasocontraction may be a contributing factor in the development of cardiovascular diseases
in populations exposed to arsenic.
Endothelial dysfunction: implications for therapy of cardiovascular diseases
The Servier Group is established in 140 countries with its main therapeutic products used to treat cardiovascular disease
, diabetes, neuropsychiatric disorders, cancer and osteoarticular diseases.
This coupled with the economic impact of cardiovascular disease
underscores the need for new therapies that will reduce the suffering and improve the quality of life of individuals affected by this devastating disease.
CardioVascular BioTherapeutics is dedicated to the development of therapies for the treatment of cardiovascular disease
, which afflicts more than 71 million people in the US.
We look forward to working with The Bruckner Group to incorporate economic evaluations into our development process, which will help us to determine the data and evidence that we need to sufficiently prove the economic benefits to payers for covering Cardio Vascu-Grow for patients suffering from cardiovascular disease